Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSThis is the last blog in the five-blog series: Creating a framework for a successful launch. IQVIA analyzed launches globally to identify common launch challenges and pitfalls. Four launch archetypes were identified, "science sells", "market shaping", "who benefits" and "emphasize the difference", each had very specific critical success factors.
IQVIA selected Orexigen Therapeutics' launch of Contrave as an example of "Emphasize the difference", used to describe drugs with high unmet need in the market and low product differentiation. When dealing with a product with that combination, the launching company would need to look at the following aspects:
Additional challenges for emerging biopharma include:
This particular case study focuses on consumer focus and share of voice.
Contrave (naltrexone/bupropion) was approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 or more, or 27 in patients with one or more related co-morbidities. Contrave was launched in 2014, where it was up against low-cost generic phentermine, and against two big pharma branded drugs, with a third joining the market seven months after.
The obesity market has some challenges, including historic safety issues in this field. Wyeth's Pondimin (fenfluramine/phentermine, also known as fen-phen) was approved in 1996 but withdrawn in 1997 after heart valve problems and deaths. There are also perceptions from patients and physicians that obesity is a lifestyle choice rather than a treatable disease, which is bolstered by the lack of protocols for its treatment.
Orexigen is an emerging biopharma company, and Contrave was its first launch onto the U.S. market. Because of the size of the obesity market and its associated issues, Orexigen granted an exclusive license to market, while retaining the ability to co-promote the treatment. Takeda's experience in the diabetes and endocrinology market, and its established field force of 900 reps, provided credibility to the physicians, and the ability to reach healthcare providers.
While the market was a busy one, it is still one with unmet need, and Contrave had a number of advantages against its competitors:
Orexigen and Takeda's product messaging highlighted Contrave's limited abuse potential as a non-scheduled drug, its improved cardiovascular safety, and its overall affordability. The companies also launched a "Resolve now: Stay ahead of the curve" campaign, targeting overweight and obese women, including those with depression. This used actress Sara Rue as a spokesperson, who encouraged women to visit a patient facing product website to enter a contest sharing their personal weight loss journey.
After its launch, Contrave overcame its brand competitors and was second in the market only to phentermine, supporting Orexigen's decision to take a partner and to use its marketing weight and know-how to reach out to consumers.
Contrave was also more actively promoted to physicians via contacts than its competitors at launch, confirming how important networks can be in promotion of drugs of this launch archetype.
To get more insight into the “emphasize the difference” archetype visit: A framework for successful biopharma launches for the recorded webinar, supported by a slide presentation.